Genentech Logo

Scientist Profile

Flavius Martin

Associate Director, Senior Scientist, Immunology
 
"There is no day that passes without my thinking about the chance we have at this time to deconstruct human disease and take advantage of the advanced tools we have to make a difference in people's lives."
 

I joined the Department of Immunology at Genentech in 2002 as a scientist because of my interest in the study of human immune driven diseases and my desire to contribute to the next generation of therapies.

As mouse immunology took me only midway to reaching this goal, I was fortunate to find an environment at Genentech with outstanding biological and medical knowledge that has identical aspirations, as well as the will and resources to succeed. Genentech's track record and current efforts are testimony to the perfect symbiosis between basic and applied research with clinical drug development.

See More

 
 
My Focus

My current work focuses on several genes expressed in myeloid cells (inflammatory macrophages and conventional dendritic cells) that play roles in normal and pathogenic immune responses.

The overall laboratory interest is to identify and decipher the biology of cells, pathways and molecules involved in human autoimmune and allergic diseases. We are interested in the pathogenic role of myeloid cells (inflammatory macrophages and conventional dendritic cells) in immunologic diseases and in rheumatoid arthritis in particular. Current work focuses on several genes expressed in these cells that play roles in normal and pathogenic immune responses. In addition, we have a long term interest in B-lymphocyte biology with focus on manipulating and optimizing tools for B-cell immunotherapy and their clinical applications.

See More

 
Publications & Recognition
  • Transplantation: It may take two to tango and to treat
  • Immunol Cell Biol 2008; 86(2): 107-8
  • Martin F.
  • Anti-BR3 antibodies - a new class of B cell immunotherapies combining cellular depletion and survival blockade
  • Blood 2007; 110(12): 3959-67
  • W.Y. Lin, Q. Gong, D. Seshasayee, Z. Lin, Q. Ou, S. Ye, E. Suto, J. Shu, W. P. Lee, V. Lee, G. Fuh, M. Leabman, S. Iyer, J. Beyer, K. Howell, T. Gelzleichter, S. Yeh, L. DeForge, D. Danilenko, J.S. Thompson, C. Ambrose, M. Balazs, M. Starovasnik and F. Martin
  • In vivo OX40L blockade inhibits TSLP-driven atopic inflammation in mice and non-human primates
  • J Clin Invest 2007; 117(12): 3868-78
  • D. Seshasayee, W.P. Lee, M. Zhou, J. Shu, E. Suto, J. Zhang, W.Y. Lin, L. Diehl, C. Austin, G. Meng, M. Tan, S. Bullens, S. Seeber, M. Fuentes, F. Rebers, L. Miller, J. Gerriets, L. Wu, S. Hymowitz and F. Martin
 
View All Publications & Recognition
 
  • University of Alabama at Birmingham
  • Research Associate
  • 1999-2002
  • University of Alabama at Birmingham
  • Postdoctoral Fellow
  • 1993-1998
  • University of Timisoara Medical School, Timisoara, Romania
  • M.D.
  • 1986-1992
  • Banat College, Timisoara, Romania
  • Baccalaureate
  • 1982-1986
Publications & Recognition
  • Transplantation: It may take two to tango and to treat
  • Immunol Cell Biol 2008; 86(2): 107-8
  • Martin F.
  • Anti-BR3 antibodies - a new class of B cell immunotherapies combining cellular depletion and survival blockade
  • Blood 2007; 110(12): 3959-67
  • W.Y. Lin, Q. Gong, D. Seshasayee, Z. Lin, Q. Ou, S. Ye, E. Suto, J. Shu, W. P. Lee, V. Lee, G. Fuh, M. Leabman, S. Iyer, J. Beyer, K. Howell, T. Gelzleichter, S. Yeh, L. DeForge, D. Danilenko, J.S. Thompson, C. Ambrose, M. Balazs, M. Starovasnik and F. Martin
  • In vivo OX40L blockade inhibits TSLP-driven atopic inflammation in mice and non-human primates
  • J Clin Invest 2007; 117(12): 3868-78
  • D. Seshasayee, W.P. Lee, M. Zhou, J. Shu, E. Suto, J. Zhang, W.Y. Lin, L. Diehl, C. Austin, G. Meng, M. Tan, S. Bullens, S. Seeber, M. Fuentes, F. Rebers, L. Miller, J. Gerriets, L. Wu, S. Hymowitz and F. Martin
  • B cell immunobiology in disease - evolving concepts from the clinic
  • Annual Review of Immunology. Annual Reviews Immunol 24:467-496, 2006
  • Martin, F. and Chan, A.C.
  • Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
  • J Immunol 2005; 174(2): 817-26
  • Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin, F., Chan AC
  • Unraveling TACIt functions
  • Nature Genetics 9 (37): 793-94, 2005
  • Martin, F. and Dixit, V.M.
  • Pathogenic roles of B cells in human autoimmunity; insights from the clinic
  • Immunity 20(5): 517-27, 2004
  • Martin, F. and Chan, A.C.
  • Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses
  • Immunity 17(3): 341-352, 2002
  • Balazs, M., Martin, F., Zhou, T., and J.F. Kearney
  • Marginal Zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens
  • Immunity 14 (5), 617-629, 2001
  • Martin, F., Oliver, A.M., and Kearney, J.F.
  • B1 cells: Similarities and differences with other B cell subsets
  • Current Opinions in Immunology 13, 195-201, 2001
  • Martin, F., and Kearney, J.F.
  • Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk
  • Immunity 12 (1), 39-49, 2000
  • Martin, F., and Kearney, J.F.
  • B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory"
  • Immunological Reviews 175, 70-79, 2000
  • Martin, F., and Kearney, J.F.
  • Selection in the mature B-cell repertoire
  • Current Topics in Microbiology and Immunology 252, 97-105, 2000
  • Martin, F., and Kearney, J.F.
  • Generation of the germline peripheral B cell repertoire: VH81X-lambda B cells are unable to complete all developmental programs
  • J. Immunol 160: 3748-3758, 1998
  • Martin, F., Won W.-J. and Kearney, J.F.